HOME >> BIOLOGY >> NEWS
New prostate cancer gene identified

Phoenix, August 8th, 2004-Researchers at the Translational Genomics Research Institute (TGen) have found a new way to speed the discovery of genes that suppress tumors, and in the process identified a gene that appears to be important in prostate cancer. The findings appeared today in the journal Nature Genetics.

The gene, not previously known to be a tumor suppressor, most likely plays a role in regulating and maintaining normal tissue organization. The researchers have shown that the gene, known as EphB2, is inactivated in prostate cancer. This is the first time abnormalities in the gene have been linked to cancer. They believe loss of the gene's function leads to disorganization of cells and also encourages the growth and survival of prostate cancer cells.

"This finding provides critical insight into the factors that cause prostate cancer, which can be used for development of additional diagnostics and therapeutics for prostate cancer," said Dr. Spyro Mousses, head of TGen's Cancer Drug Development Laboratory and the paper's senior author. "Much additional research is warranted to determine the extent of its involvement in prostate cancer and other cancers as well."

"These findings represent a significant advancement in prostate cancer research, as the number of current treatment options for advanced prostate cancer remains limited," said Dr. John Carpten, Senior Investigator at TGen, Director of its Genetic Basis of Human Disease Division, and Head of the TGen Prostate Cancer Research Unit. "The discovery of mutations in this gene allows us the opportunity to explore a new path towards treating a significant number of men with advanced prostate cancer. As TGen's mission is to translate laboratory findings into the clinic, we hope to use this information to ultimately help provide prostate cancer patients more treatment options and a better quality of life."

The study was the result of an increasing trend in genome resea
'"/>

Contact: Candice Nulsen
cnulsen@tgen.org
The Translational Genomics Research Institute
8-Aug-2004


Page: 1 2

Related biology news :

1. Lycopene slows human prostate tumour growth in mice and combined with vitamin E is even better
2. Researchers identify distinctive signature for metastatic prostate cancer
3. Charting the future in prostate cancer care: A call to action
4. Study reveals first genetic step necessary for prostate cancer growth
5. Study narrows search for genes placing men at increased risk for prostate cancer
6. MICs shed light on prostate cancer
7. Alterations in vitamin D receptor gene increase prostate, breast cancer risk
8. U-M scientists find common virus in human prostate tissue
9. Newly designed nanoparticle quantum dots simultaneously target and image prostate tumors in mice
10. Gene expression patterns may help predict risk and progression of prostate cancer
11. Muscle-derived cells and gene therapy may cure for post-prostatectomy erectile dysfunction

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
Cached News: